Projects funded by the NCN
EBI2 receptor as a new myelin repair therapy in multiple sclerosis.
2022/47/D/NZ3/02613
Keywords:
remyelination multiple sclerosis EBI2 (GPR183) cuprizone model organotypic brain slices oligodendrocytes astrocytes microglia
Descriptors:
- NZ3_006:
- NZ3_005:
- NZ4_007:
Panel:
NZ3 - Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology
Host institution :
Gdański Uniwersytet Medyczny, Wydział Lekarski
woj. pomorskie
Principal investigator (from the host institution):
Number of co-investigators in the project: 3
Call: SONATA 18 - announced on 2022-07-15
Amount awarded: 1 707 496 PLN
Project start date (Y-m-d): 2023-12-01
Project end date (Y-m-d): 2026-11-30
Project duration:: 36 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Accelerated remyelination and immune modulation by the EBI2 agonist 7α,25-dihydroxycholesterol analogue in the cuprizone modelAuthors:Klaudia Konieczna-Wolska, Fionä Caratis, Mikołaj Opiełka, Karol Biernacki, Krzysztof Urbanowicz, Joanna Klimaszewska, Piotr Pobiarzyn, Oliwier Krajewski, Sebastian Demkowicz, Ryszard T. Smoleński, Bartosz Karaszewski, Klaus Seuwen, Aleksandra RutkowskaAcademic press:Biomedicine & Pharmacotherapy (rok: 2024, tom: 181, strony: 117653), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.biopha.2024.117653 - link to the publication